Overview: AML ETO t(8;21) Qualitative TestIntroduction: The AML ETO t(8;21) Qualitative Test detects the AML1-ETO gene rearrangement to diagnose or confirm acute myeloid leukemia (AML), which may cause fatigue or frequent infections. Aligned with 2023 NCCN guidelines, it uses PCR for high specificity, critical for guiding diagnosis and treatment in molecular pathology for AML patients.
Other Names: AML ETO Qualitative Assay, t(8;21) Diagnostic Test.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards for diagnostic accuracy.
Historical Milestone: AML genetic testing advanced in the 1990s with PCR. Qualitative PCR for t(8;21) emerged in the 2000s, improving diagnostic precision.
Purpose: Diagnoses AML, confirms t(8;21) translocation, and guides treatment in patients with symptoms like fatigue or infections.
Test Parameters: 1. AML ETO t(8;21) Gene Rearrangement
Pretest Condition: No fasting required. Collect whole blood or bone marrow at any time. Report symptoms like fatigue or infections, and list chemotherapy history.
Specimen: 2-5 mL whole blood (EDTA) or 2-5 mL bone marrow (EDTA). Transport in a biohazard bag within 24 hours.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document AML symptoms, treatment history, or family history of leukemia. Include current medications, especially chemotherapy or immunosuppressive drugs.
Consent: Written consent required, detailing the tests purpose, diagnostic implications, and potential need for treatment.
Procedural Considerations: Uses qualitative PCR to detect AML ETO t(8;21). Results are available in 3-5 days, supporting rapid diagnosis.
Factors Affecting Result Accuracy: Improper storage or delayed transport can degrade nucleic acids. Contamination or low sample quality may cause false negatives.
Clinical Significance: Detection of AML ETO t(8;21) confirms AML diagnosis, prompting chemotherapy or transplant. Negative results may require additional genetic testing.
Specialist Consultation: Consult a hematologist or oncologist for result interpretation. A molecular pathologist referral is advised for complex cases.
Additional Supporting Tests: AML ETO quantitative test, flow cytometry, or cytogenetic analysis to confirm AML diagnosis or assess disease burden.
Test Limitations: Rare translocations may be missed. Results require clinical correlation with other AML markers.
References: NCCN AML Guidelines, 2023; Blood, Dohner H, 2022.
